A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2014
At a glance
- Drugs Cetuximab (Primary) ; Platinum complexes
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 07 Dec 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 03 Mar 2010 New trial record